ROCKVILLE, Md., Oct. 20, 2008 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF) today announced that Chief Executive Officer Martin Rosendale will present an overview of the Company at the Rodman & Renshaw 10th Annual Healthcare Conference on Wednesday, November 12, 2008 at 2:25 p.m. Eastern time. The conference will be held at the New York Palace Hotel in New York City.
In addition to the 20-minute presentation, Mr. Rosendale will be available for one-on-one meetings throughout the day, before and after the 2:25 p.m. presentation. To register for the conference or to request a one-on-one meeting with Cytomedix, please visit http://www.rodmanandrenshaw.com/conferences?id=19. A web cast of the presentation will be available live and for 90 days after the conference at http://www.wsw.com/webcast/rrshq14/gtf or on the Company's website at www.cytomedix.com.
ABOUT CYTOMEDIX
Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, including the AutoloGel(tm) System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood. The AutoloGel(tm) System is cleared by the Food and Drug Administration ("FDA") for use on a variety of exuding wounds. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its AutoloGel(tm) System. The Company is also moving forward with the development of other product candidates in its pipeline. Most notably is its CT-112 product, an anti-inflammatory peptide, that has shown promise in pre-clinical testing, and for which the Company is currently preparing an Investigational New Drug (IND) application for the FDA. Additional information regarding Cytomedix is available at: http://www.cytomedix.com
SAFE HARBOR STATEMENT
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, and competitive responses, Cytomedix's ability to execute on its strategy to market the AutoloGel(tm) System as contemplated. CT-112 was introduced as a therapeutic candidate with an FDA Pre-IND meeting in 1995. It is uncertain whether Cytomedix will obtain the funds necessary for development of, or whether current market conditions will support a renewed effort to develop CT-112. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.